191 related articles for article (PubMed ID: 32060993)
21. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1.
Chang TK; Chen J; Benetton SA
Drug Metab Dispos; 2002 Apr; 30(4):378-84. PubMed ID: 11901090
[TBL] [Abstract][Full Text] [Related]
22. Tight-binding inhibition by alpha-naphthoflavone of human cytochrome P450 1A2.
Cho US; Park EY; Dong MS; Park BS; Kim K; Kim KH
Biochim Biophys Acta; 2003 May; 1648(1-2):195-202. PubMed ID: 12758162
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 CYP1 metabolism of hydroxylated flavones and flavonols: Selective bioactivation of luteolin in breast cancer cells.
Wilsher NE; Arroo RR; Matsoukas MT; Tsatsakis AM; Spandidos DA; Androutsopoulos VP
Food Chem Toxicol; 2017 Dec; 110():383-394. PubMed ID: 29097115
[TBL] [Abstract][Full Text] [Related]
24. Predicting drug metabolism by CYP1A1, CYP1A2, and CYP1B1: insights from MetaSite, molecular docking and quantum chemical calculations.
Pragyan P; Kesharwani SS; Nandekar PP; Rathod V; Sangamwar AT
Mol Divers; 2014 Nov; 18(4):865-78. PubMed ID: 25028215
[TBL] [Abstract][Full Text] [Related]
25. Identification of CYP1B1-specific candidate inhibitors using combination of in silico screening, integrated knowledge-based filtering, and molecular dynamics simulations.
Kumar R; Gupta D
Chem Biol Drug Des; 2016 Nov; 88(5):730-739. PubMed ID: 27300691
[TBL] [Abstract][Full Text] [Related]
26. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1.
Chang TK; Chen J; Yeung EY
Toxicol Appl Pharmacol; 2006 May; 213(1):18-26. PubMed ID: 16226778
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors.
Dong J; Wang Z; Cui J; Meng Q; Li S
Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634
[TBL] [Abstract][Full Text] [Related]
28. Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics.
Krusekopf S; Roots I; Hildebrandt AG; Kleeberg U
Xenobiotica; 2003 Feb; 33(2):107-18. PubMed ID: 12623754
[TBL] [Abstract][Full Text] [Related]
29. Investigation of substrate recognition for cytochrome P450 1A2 mediated by water molecules using docking and molecular dynamics simulations.
Watanabe Y; Fukuyoshi S; Kato K; Hiratsuka M; Yamaotsu N; Hirono S; Gouda H; Oda A
J Mol Graph Model; 2017 Jun; 74():326-336. PubMed ID: 28475969
[TBL] [Abstract][Full Text] [Related]
30. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.
Shimada T; Gillam EM; Sutter TR; Strickland PT; Guengerich FP; Yamazaki H
Drug Metab Dispos; 1997 May; 25(5):617-22. PubMed ID: 9152602
[TBL] [Abstract][Full Text] [Related]
31. For dioxin-induced birth defects, mouse or human CYP1A2 in maternal liver protects whereas mouse CYP1A1 and CYP1B1 are inconsequential.
Dragin N; Dalton TP; Miller ML; Shertzer HG; Nebert DW
J Biol Chem; 2006 Jul; 281(27):18591-600. PubMed ID: 16636061
[TBL] [Abstract][Full Text] [Related]
32. A new class of CYP1B1 inhibitors derived from bentranil.
Yi L; Huang X; Yang M; Cai J; Jia J; Peng Z; Zhao Z; Yang F; Qiu D
Bioorg Med Chem Lett; 2023 Jan; 80():129112. PubMed ID: 36565966
[TBL] [Abstract][Full Text] [Related]
33. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
34. Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences.
Iwanari M; Nakajima M; Kizu R; Hayakawa K; Yokoi T
Arch Toxicol; 2002 Jun; 76(5-6):287-98. PubMed ID: 12107646
[TBL] [Abstract][Full Text] [Related]
35. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.
Yamaori S; Kushihara M; Yamamoto I; Watanabe K
Biochem Pharmacol; 2010 Jun; 79(11):1691-8. PubMed ID: 20117100
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of aryl hydrocarbon receptor transactivation and DNA adduct formation by CYP1 isoform-selective metabolic deactivation of benzo[a]pyrene.
Endo K; Uno S; Seki T; Ariga T; Kusumi Y; Mitsumata M; Yamada S; Makishima M
Toxicol Appl Pharmacol; 2008 Jul; 230(2):135-43. PubMed ID: 18372000
[TBL] [Abstract][Full Text] [Related]
37. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.
Androutsopoulos VP; Papakyriakou A; Vourloumis D; Spandidos DA
Bioorg Med Chem; 2011 May; 19(9):2842-9. PubMed ID: 21482471
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1.
Mikstacka R; Rimando AM; Dutkiewicz Z; Stefański T; Sobiak S
Bioorg Med Chem; 2012 Sep; 20(17):5117-26. PubMed ID: 22863525
[TBL] [Abstract][Full Text] [Related]
39. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1.
Doostdar H; Burke MD; Mayer RT
Toxicology; 2000 Apr; 144(1-3):31-8. PubMed ID: 10781868
[TBL] [Abstract][Full Text] [Related]
40. Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism.
Androutsopoulos V; Arroo RR; Hall JF; Surichan S; Potter GA
Breast Cancer Res; 2008; 10(3):R39. PubMed ID: 18454852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
